Welcome to our dedicated page for iRadimed Corporation news (Ticker: $IRMD), a resource for investors and traders seeking the latest updates and insights on iRadimed Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect iRadimed Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of iRadimed Corporation's position in the market.
IRADIMED reported record revenue of $17.6 million, GAAP diluted EPS of $0.32, and non-GAAP diluted EPS of $0.36 for the first quarter of 2024. The company also declared a regular quarterly cash dividend of $0.15 per share for the second quarter of 2024. The financial results showed an increase in operating income by 18.5% compared to the same period in 2023. The company anticipates strong financial performance for the second quarter and full year of 2024.